Drugs / YB-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07682896 | Jun 2026 → Dec 2027 expected | Graves disease | Yarrow Bioscience, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-30 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical Trials genscigroup.com ↗
Recently, GenSci098 (YB-101), an innovative anti-TSHR antibody, has advanced into Phase 2 clinical trials for Graves’ disease (GD) and thyroid eye disease (TED) and reached First Patient In (FPI), following its FDA Fast Track Designation. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-30 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical Trials genscigroup.com ↗ |
| 2026-07-27 | Yarrow Bioscience, Inc. | Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease yarrowbioscience.com ↗ |
| 2025-12-16 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW Investments genscigroup.com ↗ |
| 2025-12-15 | Yarrow Bioscience, Inc. | GenSci and RTW Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience yarrowbioscience.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07682896 ↗ |
| Route | Subcutaneous | “Participants will receive YB-101 via subcutaneous injection.” NCT07682896 ↗ |